$2,810,000 of PFIZER INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)"
You can find more data on corporate lobbying on Quiver Quantitative.
PFE Congressional Stock Trading
Members of Congress have traded $PFE stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 1 purchase worth up to $15,000 on 11/18 and 2 sales worth up to $30,000 on 12/19, 08/05.
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
PFE Hedge Fund Activity
We have seen 1,276 institutional investors add shares of PFE stock to their portfolio, and 1,389 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 24,513,278 shares (+55.9%) to their portfolio in Q3 2025, for an estimated $624,598,323
- WELLINGTON MANAGEMENT GROUP LLP removed 16,541,586 shares (-21.5%) from their portfolio in Q3 2025, for an estimated $421,479,611
- MILLENNIUM MANAGEMENT LLC removed 12,237,392 shares (-87.4%) from their portfolio in Q3 2025, for an estimated $311,808,748
- BNP PARIBAS FINANCIAL MARKETS removed 11,413,258 shares (-54.2%) from their portfolio in Q3 2025, for an estimated $290,809,813
- ROYAL BANK OF CANADA added 9,722,744 shares (+33.0%) to their portfolio in Q3 2025, for an estimated $247,735,517
- THORNBURG INVESTMENT MANAGEMENT INC removed 9,009,301 shares (-86.1%) from their portfolio in Q3 2025, for an estimated $229,556,989
- STARBOARD VALUE LP removed 8,542,149 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $217,653,956
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PFE Analyst Ratings
Wall Street analysts have issued reports on $PFE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/24/2025
To track analyst ratings and price targets for PFE, check out Quiver Quantitative's $PFE forecast page.
PFE Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 7 analysts offer price targets for $PFE in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Michael Yee from UBS set a target price of $25.0 on 01/07/2026
- Terence Flynn from Morgan Stanley set a target price of $27.0 on 12/17/2025
- Jason Gerberry from B of A Securities set a target price of $28.0 on 12/15/2025
- Geoff Meacham from Citigroup set a target price of $26.0 on 12/02/2025
- Vamil Divan from Guggenheim set a target price of $35.0 on 11/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
